Pharming Group N.V.
Pharming Group N.V., a biopharmaceutical company headquartered in the Netherlands, is at the forefront of developing innovative therapies for rare diseases. Founded in 1988, Pharming has achieved significant milestones, including the successful launch of its flagship product, Ruconest, which is used to treat hereditary angioedema. With a strong focus on protein replacement therapies, Pharming operates primarily in Europe and North America, positioning itself as a leader in the biopharmaceutical industry. The company is dedicated to addressing unmet medical needs through its unique recombinant technology, which sets its products apart in the market. Notably, Pharming has garnered recognition for its commitment to research and development, solidifying its reputation as a key player in the field of rare disease treatment.
DitchCarbon Score
How does Pharming Group N.V.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharming Group N.V.'s score of 25 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pharming Group N.V.'s reported carbon emissions
Pharming Group N.V., headquartered in the Netherlands (NL), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. As of now, Pharming Group N.V. does not inherit emissions data from any parent or related organizations, and there are no initiatives such as Science Based Targets Initiative (SBTi) or other climate commitments reported. This lack of data suggests that the company may still be in the early stages of developing a comprehensive climate strategy or reporting framework. In the context of the pharmaceutical industry, it is increasingly important for companies to establish clear emissions reduction targets and commitments to align with global climate goals. As Pharming Group N.V. progresses, it may consider adopting industry-standard practices to enhance its sustainability profile and contribute to climate action.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pharming Group N.V. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
